IIFL Securities Stock Idea: Buy Jubilant Pharmova with Target Rs 695

IIFL Securities has recommended a buy call on Jubilant Pharmova with a target price of Rs 695, suggesting a potential upside of over 3%. The current market price of the stock is Rs 673. This recommendation is based on the company's strong fundamentals, including its diverse portfolio of products, robust financial performance, and growth potential in emerging markets. Analysts believe that Jubilant Pharmova is well-positioned to benefit from increasing healthcare spending and the growing demand for pharmaceuticals globally.

About Jubilant Pharmova:

Jubilant Pharmova Limited is a global pharmaceutical company headquartered in Noida, India. It is a subsidiary of Jubilant Life Sciences Limited. The company manufactures and markets a wide range of pharmaceutical products, including active pharmaceutical ingredients (APIs), generics, specialty pharmaceuticals, and nutraceuticals. Jubilant Pharmova operates in over 40 countries and has manufacturing facilities in India, the United States, Canada, and the United Kingdom. The company's products are used to treat a variety of therapeutic areas, including oncology, neurology, cardiology, and dermatology. Jubilant Pharmova is a leading supplier of APIs to the pharmaceutical industry and is also a major player in the generics market.

52 Week Price Trend:

Currently trading at Rs 673, Jubilant Pharmova has witnessed a significant surge since its 52-week low of Rs 268.8. This notable gain of over 150% reflects the company's robust performance and positive market sentiment. However, the stock remains below its 52-week high of Rs 627.45, indicating potential for further growth. Investors should carefully consider the company's fundamentals, market outlook, and risk appetite before making investment decisions.

Stratzy's MOST Analysis:

JublPharma has been rated BB- by Stratzy's MOST framework, indicating medium fundamental risks. This rating is based on an assessment of the company's management, outlook, safety, and trend. The framework assigns scores to each pillar, with higher scores indicating lower risks. JublPharma's rating of BB- suggests that while the company has some strengths, there are also areas where it could improve its fundamental position.

Company's Fundamentals:

Jubilant Pharmova (NSE: JUBLPHARMA) is a pharmaceutical company listed on the National Stock Exchange (NSE) of India. The company's stock is currently trading at a Price-to-Earnings (PE) ratio of 250.88, indicating that investors are willing to pay Rs. 250.88 for every rupee of earnings. The Price-to-Book (PB) ratio is 1.7, which suggests that the company's market value is 1.7 times its book value. The Dividend Yield of 0.87% indicates that the company pays dividends to its shareholders, yielding a return of 0.87% on the current stock price. These metrics provide insights into the company's financial performance and valuation, helping investors make informed investment decisions.

Fundamental and Technical information provided in this blog were last updated on 16 Apr, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.